PRF Technologies

PRF Technologies Capital Expenditures

The Capital Expenditures (CapEx) of PRF Technologies (PRFX) as of Nov 4, 2026 is -2,000.00 USD. In the previous year, Capital Expenditures (CapEx) was -13,000.00 USD — a change of -84.62% (higher).

Capital Expenditures

-2,000.00USD

YoY

-84.62%

Last updated:

Capital Expenditures (CapEx) of PRF Technologies is 2025 -2,000.00 USD. Capital Expenditures (CapEx) of PRF Technologies was 2024 -13,000.00 USD. It decreases by -84.62% higher compared to the previous year.

The PRF Technologies Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-10,000.00 USD
Jan 1, 2019
-10,000.00 USD
Jan 1, 2020
-10,000.00 USD
Jan 1, 2021
-50,000.00 USD
Jan 1, 2022
-6,000.00 USD
Jan 1, 2023
-9,000.00 USD
Jan 1, 2024
-13,000.00 USD
Jan 1, 2025
-2,000.00 USD
The PRF Technologies Capital Expenditures history
YEARCapital ExpendituresYoY
-2,000.00USD-84.62%
-13,000.00USD+44.44%
-9,000.00USD+50.00%
-6,000.00USD-88.00%
-50,000.00USD+400.00%
-10,000.00USD0.00%
-10,000.00USD0.00%
-10,000.00USD0.00%
-10,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRF Technologies Stock analysis

What does PRF Technologies do? PainReform Ltd. develops reformulated pain therapeutics to extend efficacy, minimize adverse effects, and improve patient convenience. The company focuses on enhancing established pharmaceuticals through its proprietary technology, targeting faster recovery of motor function. Its products are designed for healthcare providers and patients seeking advanced pain management solutions. The business model centers on licensing its reformulation technology to pharmaceutical partners. These partners integrate PainReform's solutions into their existing drug portfolios, leveraging the technology to improve product performance without developing new compounds from scratch. The primary buyers are established pharmaceutical companies looking to extend patent life and enhance market competitiveness of their pain management drugs. PainReform's technology addresses key pain management challenges by prolonging drug effects and reducing side effects. This positions the company as a strategic partner for pharmaceutical firms aiming to optimize their therapeutic offerings. The target segments include chronic pain patients and healthcare systems seeking more effective and safer pain treatment options. PRF Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PRF Technologies stock

Capital Expenditures (CapEx) of PRF Technologies is -2,000.00 USD in 2025.

Capital Expenditures (CapEx) of PRF Technologies changed from -13,000.00 USD to -2,000.00 USD, representing a -84.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) PRF Technologies since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s PRF Technologies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PRF Technologies

All Key Metrics — PRF Technologies